



## EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases

J N Hoes, J W G Jacobs, M Boers, D Boumpas, F Buttgereit, N Caeyers, E H Choy, M Cutolo, J A P Da Silva, G Esselens, L Guillemin, I Hafstrom, J R Kirwan, J Rovinsky, A Russell, K G Saag, B Svensson, R Westhovens, H Zeidler and J W J Bijlsma

*Ann Rheum Dis* 2007;66:1560-1567; originally published online 27 Jul 2007;  
doi:10.1136/ard.2007.072157

---

Updated information and services can be found at:

<http://ard.bmj.com/cgi/content/full/66/12/1560>

---

*These include:*

**Data supplement**

*"web only appendix"*

<http://ard.bmj.com/cgi/content/full/ard.2007.072157/DC1>

**References**

This article cites 74 articles, 38 of which can be accessed free at:

<http://ard.bmj.com/cgi/content/full/66/12/1560#BIBL>

2 online articles that cite this article can be accessed at:

<http://ard.bmj.com/cgi/content/full/66/12/1560#otherarticles>

**Rapid responses**

You can respond to this article at:

<http://ard.bmj.com/cgi/eletter-submit/66/12/1560>

**Email alerting  
service**

Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article

---

**Notes**

---

To order reprints of this article go to:

<http://journals.bmj.com/cgi/reprintform>

To subscribe to *Annals of the Rheumatic Diseases* go to:

<http://journals.bmj.com/subscriptions/>

## EXTENDED REPORT

## EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases

J N Hoes, J W G Jacobs, M Boers, D Boumpas, F Buttgerit, N Caeyers, E H Choy, M Cutolo, J A P Da Silva, G Esselens, L Guillevin, I Hafstrom, J R Kirwan, J Rovensky, A Russell, K G Saag, B Svensson, R Westhovens, H Zeidler, J W J Bijlsma



This is an abbreviated version of the article; the full version is available online at <http://ard.bmj.com/supplemental>

See end of article for authors' affiliations

Correspondence to: J N Hoes, Department of Rheumatology & Clinical Immunology (F02.127), University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands; [mail@hoesjn.org](mailto:mail@hoesjn.org)

Accepted 22 July 2007

*Ann Rheum Dis* 2007;**66**:1560–1567. doi: 10.1136/ard.2007.072157

**Objective:** To develop evidence-based recommendations for the management of systemic glucocorticoid (GC) therapy in rheumatic diseases.

**Methods:** The multidisciplinary guideline development group from 11 European countries, Canada and the USA consisted of 15 rheumatologists, 1 internist, 1 rheumatologist–epidemiologist, 1 health professional, 1 patient and 1 research fellow. The Delphi method was used to agree on 10 key propositions related to the safe use of GCs. A systematic literature search of PUBMED, EMBASE, CINAHL, and Cochrane Library was then used to identify the best available research evidence to support each of the 10 propositions. The strength of recommendation was given according to research evidence, clinical expertise and perceived patient preference.

**Results:** The 10 propositions were generated through three Delphi rounds and included patient education, risk factors, adverse effects, concomitant therapy (ie, non-steroidal anti-inflammatory drugs, gastroprotection and cyclo-oxygenase-2 selective inhibitors, calcium and vitamin D, bisphosphonates) and special safety advice (ie, adrenal insufficiency, pregnancy, growth impairment).

**Conclusion:** Ten key recommendations for the management of systemic GC-therapy were formulated using a combination of systematically retrieved research evidence and expert consensus. There are areas of importance that have little evidence (ie, dosing and tapering strategies, timing, risk factors and monitoring for adverse effects, perioperative GC-replacement) and need further research; therefore also a research agenda was composed.

Since 1948, glucocorticoids (GCs) have been widely used in medicine.<sup>1</sup> Although GCs soon became associated with the occurrence of adverse effects (AEs), they are still the most frequently used anti-inflammatory and immune-suppressive drugs in rheumatic diseases. Recent studies have demonstrated the disease-modifying potential of low-dose GCs in rheumatoid arthritis (RA) and this has renewed the debate on the risk–benefit ratio of this treatment.<sup>2</sup> Current literature on the risk–benefit ratio of GCs is nevertheless inconsistent, and inappropriate use of GCs could lead to increased toxicity;<sup>3</sup> this emphasises the need for clear statements on proper use of GCs. Hence, a EULAR task force on GCs, including a patient, was formed to develop evidence-based recommendations, to provide a tool for the better use and management of GC-therapy in rheumatic diseases.

## METHODS

Endorsed by EULAR-ESCISIT, a multidisciplinary guideline development committee on GCs was formed, consisting of 20 experts in the field of GCs from 11 European countries, Canada and the USA: 15 rheumatologists, 1 internist, 1 rheumatologist–epidemiologist, 1 health professional, 1 patient and 1 research fellow. The Delphi method was used to agree on 10 key propositions related to the risk–benefit ratio of GCs, and EULAR standardised operating procedures<sup>4</sup> were then followed: (1) to identify and critically appraise research evidence for the 10 propositions, performing a systematic literature search of PUBMED, EMBASE, CINAHL and Cochrane Library; (2) to generate and validate recommendations based on the best available evidence, according to research, clinical expertise and

perceived patient preference (levels of evidence are defined in table 1); and (3) to formulate a future research agenda.

## RESULTS

First, a general literature search was performed (appendix 1 of the full version of the article; available web-only at <http://www.annrheumdis.com/supplemental>), including the estimated incidence of different types of AEs as derived from studies reporting on frequencies of AEs of GCs (see fig 1 and table 2). Second, after the taskforce experts had discussed the results of this general literature search, the Delphi exercise was initiated. At the start, 153 (partly overlapping) propositions were produced, and after 2 anonymous Delphi rounds 10 final propositions were agreed upon (table 3). Third, proposition-specific searches were done, resulting in 5089 potentially useful studies, of which 165 were included to provide (circumstantial) evidence for propositions (table 4).

## Recommendations


1. The adverse effects of glucocorticoid therapy should be considered and discussed with the patient before glucocorticoid therapy is started. This advice should be reinforced by giving information regarding glucocorticoid management. If glucocorticoids are to be used for a more prolonged period of time, a “glucocorticoid card” is to be issued to every patient, with the

**Abbreviations:** AE, adverse effect; BMD, bone-mineral density; DMARD, disease-modifying antirheumatic drug; GC, glucocorticoid; GCA, giant cell arthritis; GHR, growth-hormone replacement; NSAID, non-steroidal anti-inflammatory drug; PMR, polymyalgia rheumatica; PPI, proton pump inhibitor; RA, rheumatoid arthritis

**Table 1** Levels of evidence

I-A	Meta-analysis of randomised controlled trials
I-B	Randomised controlled trial
II-A	Controlled study without randomisation
II-B	Quasi-experimental study
III	Descriptive studies (comparative, correlation, case-control)
IV	Expert committee reports/opinions and/or clinical opinion of respected authorities

Other rheumatic  
diseases  
(PM/DM, SLE,  
Sjögren, or  
combinations)

**Figure 1** Different study populations of the included studies from the general search.

date of commencement of treatment, the initial dosage and the subsequent reductions and maintenance regimens.

- Level of evidence: IV
- Strength of recommendation (95% CI):
  - Overall: 91 (86 to 96)
  - Pretreatment advice: 92 (85 to 100)
  - Information: 88 (80 to 96)
  - Glucocorticoid card: 78 (67 to 89)

We recommend that the frequency of AEs during GC-therapy (table 2) should be categorised following WHO guidelines: very common ( $>1/10$  patients); common ( $>1/100$ ); uncommon ( $>1/1000$ ); rare ( $>1/10\ 000$ ); very rare ( $<1/100\ 000$ ).<sup>5</sup>

Detailed discussion of common and very common AEs of therapy is an integral part of the management of any disease and of patient education. Because patients' perspectives on AEs might differ from doctors' perspectives, patient information should include both perspectives (category IV evidence). In a population-based cohort, 68% of patients who used GCs recalled discussing potential GC-related AEs with their practitioner.<sup>6</sup> This recall might be influenced by the perception of severity of GC-related AEs, which may differ among patients.<sup>7</sup>

Whether discussion of possible AEs before GC-therapy has any beneficial effect on disease outcome—for example by improving patient compliance—is unclear because of lacking data. However, general patient education, including discussing possible AEs of other treatment, positively influences outcome of therapy.<sup>8–11</sup> In contrast, in a controlled clinical study the knowledge about AEs of beta-blockers produced anxiety.<sup>12</sup> So, in giving information, individual patient psychological characteristics should be taken into account. The format of patient education—for example the use of information leaflets—has not been investigated in long-term GC-therapy, so this part of the recommendation is also supported by expert opinion only. Likewise, no evidence was found to support the use of "glucocorticoid cards", but the use of a pocket card in methotrexate (MTX) users improved patients' knowledge on safety and toxicity of MTX.<sup>9</sup>

2. Initial dose, dose reduction and long-term dosing depend on the underlying rheumatic disease, disease activity, risk factors and individual responsiveness of the patient. Timing may be important, with respect to the circadian rhythm of both the disease and the natural secretion of glucocorticoids.

- Level of evidence: I–III
- Strength of recommendation (95% CI):
  - Overall: 83 (70 to 97)
  - Dose regimens: 92 (83 to 100)
  - Dose timing: 74 (59 to 89)

**Table 2** Reported AEs in GC-treated patients with rheumatic diseases: results of the general search

Type of AE	Median: (25th to 75th percentiles) (AEs per 100 patient years)
Cardiovascular (dyslipidemia, water and electrolyte imbalance, oedema, renal and heart dysfunction, hypertension)	15 (3 to 28)
Infectious (viral, bacterial, skin infections)	15 (3 to 15)
Gastro-intestinal (peptic ulcer disease, pancreatitis)	10 (4 to 20)
Psychological and behavioural (minor mood disturbances, steroid psychosis)	9 (2 to 236)
Endocrine and metabolic (glucose intolerance and diabetes, fat redistribution, interference with hormone secretion)	7 (3 to 34)
Dermatological (cutaneous atrophy, acne, hirsutism, alopecia)	5 (2 to 80)
Musculoskeletal (osteoporosis, osteonecrosis, myopathy)	4 (3 to 9)
Ophthalmological (glaucoma, cataract)	4 (0 to 5)

This table summarises reported AEs in studies ( $n = 18$ ) of the general search of patients using GCs ( $n = 963$ ) for a rheumatic disease. Only those studies of patients who were using GCs up to 30 mg prednisolone or equivalent and reporting dichotomous AE outcomes were included in the data of the table, which was used as introductory information for the taskforce. Raw data, not corrected for disease activity, co-morbidity and the frequency of AEs in the contrast group, if present, were used. So, not all AEs can be specifically attributed to the use of GCs; common events may be overestimated and less common ones underestimated. For instance, cardiovascular events are poorly correlated with GC-use. Types of AEs were divided into different groups (as has been published before<sup>23</sup>) and per group AEs per 100 patient years were derived by dividing the number of AEs by the duration of follow-up in years, times 100. The mean daily GC-dose was 8 mg, and the average duration of the studies was 19.6 months.

**Table 3** Experts' propositions developed throughout 3 Delphi rounds including the strength of recommendation

Proposition	SOR		Evidence level of data
	VAS 100 (95% CI)	A+B %	
1 a The adverse effects of glucocorticoid therapy should be considered and discussed with the patient before glucocorticoid therapy is started	92 (85 to 100)	93	IV
1 b This advice should be reinforced by giving information regarding glucocorticoid management	88 (80 to 96)	93	IV
1 c If glucocorticoids are to be used for a more prolonged period of time, a "glucocorticoid card" is to be issued to every patient, with the date of commencement of treatment, the initial dosage and the subsequent reductions and maintenance regimens	78 (67 to 89)	79	IV
1 Full proposition (1A+1B+1C)	91 (86 to 96)	92	
2 a Initial dose, dose reduction and long-term dosing depend on the underlying rheumatic disease, disease activity, risk factors and individual responsiveness of the patient	92 (83 to 100)	86	IA–III
2 b Timing may be important, with respect to the circadian rhythm of both the disease and the natural secretion of glucocorticoids	74 (59 to 89)	57	–
2 Full proposition (2A+2B)	83 (70 to 97)	85	
3 When it is decided to start glucocorticoid treatment, comorbidities and risk factors for adverse effects should be evaluated and treated where indicated; these include hypertension, diabetes, peptic ulcer, recent fractures, presence of cataract or glaucoma, presence of (chronic) infections, dyslipidaemia and comedication with non-steroidal anti-inflammatory drugs	92 (87 to 96)	100	IV
4 For prolonged treatment, the glucocorticoid dosage should be kept to a minimum, and a glucocorticoid taper should be attempted in case of remission or low disease activity; the reasons to continue glucocorticoid therapy should be regularly checked	81 (68 to 94)	86	IV
5 During treatment, patients should be monitored for body weight, blood pressure, peripheral oedema, cardiac insufficiency, serum lipids, blood and/or urine glucose and ocular pressure depending on individual patient's risk, glucocorticoid dose and duration	89 (81 to 97)	93	IV
6a If a patient is started on prednisone $\geq 7.5$ mg daily and continues on prednisone for more than 3 months, calcium and vitamin D supplementation should be prescribed	95 (91 to 99)	100	IA
6b Antiresorptive therapy with bisphosphonates to reduce the risk of glucocorticoid-induced osteoporosis should be based on risk factors, including bone-mineral density measurement	96 (92 to 99)	93	IB–III
6 Full proposition (6A+6B)	95 (89 to 100)	100	
7 Patients treated with glucocorticoids and concomitant non-steroidal anti-inflammatory drugs should be given appropriate gastro-protective medication, such as proton pump inhibitors or misoprostol, or alternatively could switch to a cyclo-oxygenase-2 selective inhibitor	91 (84 to 99)	93	1A–IB
8 All patients on glucocorticoid therapy for longer than 1 month, who will undergo surgery, need perioperative management with adequate glucocorticoid replacement to overcome potential adrenal insufficiency	91 (84 to 99)	93	IV
9 Glucocorticoids during pregnancy have no additional risk for mother and child	87 (78 to 96)	86	IB–III
10 Children receiving glucocorticoids should be checked regularly for linear growth and considered for growth-hormone replacement in case of growth impairment	93 (85 to 100)	93	IB

\*A+B%, percentage of the taskforce members that strongly to fully recommended this proposition, based on an A–E ordinal scale; CI, confidence interval; SOR, strength of recommendation; VAS, visual analogue scale (0–100 mm, 0 = not recommended at all, 100 = fully recommended).

Dosing strategies were assessed in one retrospective and three prospective studies on short- to intermediate-term GC treatment in polymyalgia rheumatica (PMR) and giant cell arthritis (GCA) patients needing low initial dosages had fewer relapses and lower maintenance dose, and experienced less toxicity (category III).<sup>13–16</sup> In early RA (disease duration <2 years), the use of low-dose GCs is based not solely on disease symptoms, but also on joint sparing effects on the long-term, as GCs can be categorised as disease-modifying antirheumatic drugs (DMARDs) (category IA).<sup>2</sup> Different regimens with GCs have been used for joint sparing purposes in early RA, usually

in combination with other DMARDs. These different schemes could result in different disease outcomes, but data are lacking.

A relation between dose strategies and risk factors, such as diabetes, hypertension and osteoporosis, can only be shown indirectly (category IIB–III).<sup>17–20</sup> It is unknown whether an individual response on the same GC-dose is different among individuals, since no study was found on the relation between dose strategies and individual responsiveness of patients.

The timing of GC-administration might influence its efficacy, as both signs and symptoms (such as morning stiffness) of RA<sup>21</sup> as well as serum levels of several pro-inflammatory cytokines<sup>22</sup>

**Table 4** Evidence delivered by the proposition-specific searches

Proposition	Proposition-specific search, n studies	No. of studies meeting inclusion criteria	Type of evidence*
1	2699	34	Circumstantial
2	556	16	Partially direct
3	464	29	Circumstantial
4	131	4	Circumstantial
5	401	4	Circumstantial
6	71	19	Indirect
7	157	15	Indirect
8	303	13	Circumstantial
9	86	19	Partially indirect and partially direct
10	221	19	Indirect
Total	5089	172 (165 minus duplicates)	

\*Indirect: data directly support the proposition. Circumstantial: no data directly or indirectly support the proposition, but there are circumstantial data which are useful to the proposition. Partially direct: part of the proposition is directly supported by data.

**Table 5** Theoretical framework of criteria which can be used to decide whether monitoring for specific AEs is useful

	No. needed to screen? (1/prevalence per year)	Severity? (Low/moderate/high)	Cost of screening? (Low/moderate/high)	Feasibility of scoring? (Low/moderate/high)
Body weight	1.5 <sup>6</sup>	Low	Low	High
Blood pressure	?	Moderate	Low	High
Peripheral oedema	?	Low	Low	High
Heart failure	?	High	Moderate	Moderate*
Dyslipidemia	?	Moderate	Moderate	Moderate*
Blood/urine glucose	12.5 <sup>6</sup>	Moderate	Moderate	High
Glaucoma	18.1 <sup>84</sup>	Moderate	Moderate	Moderate*

\*Scoring in daily practice depends on presence of accurate laboratory tests and/or eye-pressure measurement equipment.

show a circadian rhythm with a flare at the beginning of the day. Administration of GCs early in the morning<sup>23</sup> (category IB), or the use of modified release tablet of prednisone, delivering the GC early in the morning (abstract)<sup>24</sup> gave more improvement of RA symptoms than conventional timing of GC-therapy.

In conclusion, there is category III evidence on dosing regimens of GCs in PMR/GCA and category IA evidence showing a benefit for the use of low-dose long-term GCs in early RA. The relation between risk factors, AEs, high GC-dosages and long-term GC-use was indirectly shown for diabetes (category IIB) and hypertension (category III). No study was identified on individual responsiveness to GC (category IV). There are category IB data on a superior effect of circadian administration of GCs.

3. When it is decided to start glucocorticoid treatment, comorbidities and risk factors for adverse effects should be evaluated and treated where indicated. These include hypertension, diabetes, peptic ulcer, recent fractures, presence of cataract or glaucoma, presence of (chronic) infections, dyslipidemia and co-medication with non-steroidal anti-inflammatory drugs.

- Level of evidence: IV
- Strength of recommendation (95% CI): 92 (87 to 96)

Even though the above-mentioned risk factors for GC-associated AEs are well known,<sup>25</sup> and there is obvious face validity trying to prevent these from occurring by assessing and

treating comorbidities and risk factors at baseline, there is no evidence to show that this is effective (category IV).

4. For prolonged treatment, the glucocorticoid dosage should be kept to a minimum, and a glucocorticoid taper should be attempted in case of remission or low disease activity. The reasons to continue glucocorticoid therapy should be checked regularly.


- Level of evidence: IV
- Strength of recommendation (95% CI): 81 (68 to 94)

This proposition is supported by expert opinion alone, although this proposition has obvious face validity, since the occurrence of GC-related AEs, osteoporosis in particular (proposition 5 and 6), is dependent on dose and duration of therapy.

5. During treatment, patients should be monitored for body weight, blood pressure, peripheral oedema, cardiac insufficiency, serum lipids, blood and/or urine glucose and ocular pressure depending on individual patient's risk, glucocorticoid dose and duration.

- Level of evidence: IV
- Strength of recommendation (95% CI): 89 (81 to 97)

There is no direct evidence from appropriately designed studies to support this proposition (category IV). Since risks of AEs during GC-treatment are related to GC-dose and duration of treatment, monitoring should be dependent on both

**Figure 2** Example of an algorithm for osteoporosis prevention in glucocorticoid users.



variables. Furthermore, monitoring for an AE is especially useful if the AE is preventable or treatable, common, severe, and if the cost of screening is low and monitoring is feasible in daily clinical practice. Also, non-modifiable AEs should be assessed, as they could be important from the patient's perspective and could be a surrogate marker for other AEs (eg, reflecting patient's sensitivity to GCs), alerting the physician. A theoretical framework showing elements of the discussion on monitoring the above-mentioned AEs is found in table 5, based upon group consensus after discussing all propositions.

6. If a patient is started on prednisone  $\geq 7.5$  mg daily and continues on prednisone for more than 3 months, calcium and vitamin D supplementation should be prescribed. Antiresorptive therapy with bisphosphonates to reduce the risk of glucocorticoid-induced osteoporosis should be based on risk factors, including bone-mineral density (BMD) measurement.

- Level of evidence: I
- Strength of recommendation (95% CI):
  - Overall: 95 (89 to 100)
  - Calcium and vitamin D: 95 (91 to 99)
  - Bisphosphonates: 96 (92 to 99)

Calcium and vitamin D supplementation have been shown to reduce GC-induced bone loss and fractures (category IA).<sup>26–27</sup> However, they do not totally prevent GC-induced bone loss, in contrast to bisphosphonates, which have been proven superior in this respect (category IA).<sup>28</sup> Bisphosphonate therapy can be indicated, based on the following risk factors: decreased BMD, female gender, older age, postmenopausal status and low body mass index (category IIB).<sup>29</sup> Both GC-dose and low BMD have been shown to be predictors of fractures, but at the same BMD level, postmenopausal patients on GCs were more prone to getting fractures than postmenopausal patients without this therapy (category IB).<sup>30</sup> The ACR has published a clear guideline on the treatment of GC-induced osteoporosis,<sup>31</sup> and several algorithms have been proposed to decide whether or not to start with bisphosphonates based on GC-dosage, pre-existent fractures, age and gender, menopause, and BMD measurement<sup>32–33</sup> (fig 2 gives an example).

7. Patients treated with glucocorticoids and concomitant non-steroidal anti-inflammatory drugs (NSAIDs) should be given appropriate gastro-protective medication, such as proton pump inhibitors (PPIs) or misoprostol, or alternatively could switch to a cyclo-oxygenase-2 selective inhibitor (coxib).

- Level of evidence: I
- Strength of recommendation (95% CI): 91 (84 to 98)

No study investigated gastro-protective measures in GC-using patients specifically, but the rationale for this proposition is given by the fact that gastro-intestinal (GI) toxicity possibly increases by treatment with GCs alone (see proposition 3). Likewise, although not studied in GC-using patients specifically, several treatment regimens have been shown to be gastro-protective for conventional NSAID users. Proton pump inhibitors (PPIs) and misoprostol reduce the risk of gastric and duodenal ulcers in patients taking conventional NSAIDs (category I B),<sup>34–35</sup> and cyclo-oxygenase-2 inhibitors cause less GI toxicity than conventional NSAIDs in RA patients (category I B).<sup>36–38</sup> However, conventional NSAIDs combined with PPI cause less dyspepsia than cyclo-oxygenase-2 inhibitors do (category I A).<sup>39</sup> In deciding on the prescription of cyclo-oxygenase-2 inhibitors and conventional NSAIDs, cardiovascular risk factors should also be taken into account.<sup>40–45</sup>

8. All patients on glucocorticoid therapy for longer than 1 month, who will undergo surgery, need perioperative

management with adequate glucocorticoid replacement to overcome potential adrenal insufficiency.

- Level of evidence: IV
- Strength of recommendation (95% CI): 91 (84–99)

Adrenal insufficiency due to surgical stress has already been described in the 1950s.<sup>46</sup> As patients with RA and PMR are considered to have relative adrenal insufficiency due to their disease,<sup>47</sup> they might be more prone to adrenal insufficiency at surgery. The incidence and duration of GC-induced adrenal insufficiency depend, apart from possible individual differences in sensitivity for GC, on the type and dosage of GC<sup>48–49</sup> and the duration of therapy. GC-treatment of less than 3 weeks or alternate-day therapy does not exclude the risk of suppression of the hypothalamic-pituitary-adrenal axis,<sup>50–51</sup> but the risk is still dose-dependent.<sup>52</sup>

GC-replacement is recommended in case of surgery for patients at risk of adrenal insufficiency (category IV). For moderate physical stress-inducing procedures, a single dose of 100 mg of hydrocortisone intravenously has been proposed, and for major surgery, 100 mg of hydrocortisone intravenously before anaesthesia and every 8 h 4 times thereafter.<sup>53</sup> The dose can be gradually tapered by half per day afterwards. However, several other schemes of GC-replacement exist.

9. Glucocorticoids during pregnancy have no additional risk for mother and child.

- Level of evidence:
  - Mother: IV
  - Child: I–III
- Strength of recommendation (95% CI): 87 (78 to 96)

Safety of GC-usage during pregnancy refers to both the mother and the unborn child. First, for the pregnant mother, the spectrum of AEs associated with the use of GCs is believed not to differ between a pregnant patient and a non-pregnant patient (category IV evidence), but since pregnant or lactating women are more at risk for pregnancy-associated AEs, which are also seen as AE of GC-therapy (eg, osteoporosis,<sup>54</sup> diabetes,<sup>55</sup> hypertension<sup>56</sup>), this risk of these AEs could be especially increased by GC-therapy for these women, but no data are available.

Second, regarding the safety of GCs for the fetus and neonate, dexamethasone can be used to treat fetal conditions such as immature lungs, because it is not metabolised well by the placenta, and so higher dosages are available to the fetus. Prednisone, prednisolone and methylprednisolone are less available to the fetus (10% of the maternal dose), and so these substances are preferred for the treatment of maternal disorders.<sup>57</sup> GCs prior to and during pregnancy do not seem to have a negative impact on the development of the fetus. GCs in high doses have caused low birth weights in humans and cleft palate in experimental animal models,<sup>58–59</sup> but there is no evidence that in humans prednisone or methylprednisolone are teratogenic (Food and Drug Administration risk category B,<sup>60</sup>), category III evidence.<sup>61</sup> The incidence of infection was not increased in neonates who had been exposed to GCs in utero (category IB).<sup>62</sup>

GCs are excreted minimally into breast milk,<sup>63–64</sup> and breastfeeding by women on low-dose GC-therapy is generally considered to be safe.<sup>65</sup> Exposure of an infant can be further minimised if breastfeeding is avoided during the first 4 h after GC-intake, because there is an equilibrium between the concentration of prednisolone in mother milk and serum.<sup>64</sup>

10. Children receiving glucocorticoids should be checked regularly for linear growth and considered for growth-hormone replacement in case of growth impairment.

**Table 6** Research agenda developed throughout 2 Delphi rounds

1	What is the perception of patients, general physicians and rheumatologists on efficacy, safety and management of glucocorticoid therapy in rheumatic diseases? (exploring perceptions and environmental factors as barriers for the effective and safe use of glucocorticoids).
2	What is the influence of low-dose glucocorticoid therapy on lipid profile and other cardiovascular risk factors in relation to active inflammation?
3	What is the pathophysiology of the skin side effects due to the use of glucocorticoids, and how can these be prevented?
4	What is the ideal timing of glucocorticoid treatment regarding safety as well as efficacy?
5	Regarding the use of glucocorticoids in early RA: is a continuous low dose as effective as a step-down dose (starting high and then tapering)?
6	Can we define biomarkers (including genetics) that predict glucocorticoid toxicity?
7	What is the best strategy for prediction, detection and prevention of glucocorticoid-associated cataract and glaucoma?
8	The mechanisms behind individual responsiveness and glucocorticoid resistance should be investigated and the clinical implications clarified.
9	Do glucocorticoids also inhibit radiographic progression in patients with longstanding rheumatoid arthritis?
10	What is the pathophysiological mechanism of steroid myopathy, and can we prevent this; is there a role for specific exercises?
11	Which genomic and non-genomic mechanisms of glucocorticoid actions are responsible for wanted and adverse effects, respectively?

- Level of evidence: I
- Strength of recommendation (95% CI): 93 (85 to 100)

GCs can cause growth retardation in children (category I B).<sup>66–69</sup> The pathogenesis of this growth impairment is multifaceted. Growth-hormone replacement (GHR) can be used to prevent growth impairment due to GCs: an increase in linear growth with GHR was shown in several studies of GC-using JIA patients (category I–III),<sup>70–75</sup> and in studies of “slowly growing GC-treated patients” (category II).<sup>76–77</sup> The daily GC-doses used in these studies varied between 0.2 and 0.5 mg/kg prednisolone equivalent, and the duration GHR therapy was 2–4 years.

If GHR is considered, referral to an experienced paediatrician is indicated (category IV evidence), and additional testing can confirm growth-hormone deficiency. Routine usage of GHR in GC-using patients is hampered by several factors: the therapy involves daily injections (subcutaneously or intramuscularly), the length gain is relatively small, and it is a very costly therapy (between €15 000 and €50 000 annually, depending on the weight of the individual child<sup>78</sup>).

## DISCUSSION

This EULAR document on the safer use of systemic GCs in rheumatic diseases used a similar design to that of earlier EULAR taskforces,<sup>79–82</sup> i.e. a combination of both evidence and expert opinion. The added value of this taskforce, like previous ones, is provided by the fact that they (1) are a broad representation of experts in the field of GCs within and outside Europe; (2) use recent research data; and (3) use a thorough evidence-based format. The order of 10 propositions in the paper does not reflect importance, but more or less the logical order of patient management. Both the level of evidence of each proposition and the strength of recommendations are given. This approach has led to a reduction of personal bias, good external validity and generalisability, and clear identification of areas of clinical practice where more research data are required.<sup>83</sup> The propositions promote the safer use of GCs among physicians and patients alike in daily clinical practice, and they will form the basis of further EULAR research and education.

These recommendations have some limitations. Since GCs are used quite extensively, the search results were often overwhelming. To overcome this, we used more specific search strategies in which relevant studies might have been overlooked. Second, the selection of circumstantial evidence in the absence of direct evidence has some degree of subjectivity. Third, in the literature, the evidence hierarchy has focused on treatment efficacy, whereas evidence on safety might be better graded by other study types than RCTs. Other grading systems might be preferred for grading future studies on safety.

The literature search showed that studies on GCs in general lack a systemic assessment of AEs and that AEs often are poorly

described, let alone defined, which made it difficult to provide direct evidence for most propositions. It is therefore advisable to monitor a well-defined list of AEs in a standardised manner in future studies, taking into account patients' perspectives, but standardised scoring for most AEs has yet to be developed. Hypertension, diabetes, osteoporosis, gastric ulcer, cataract, glaucoma, infections, and dyslipidaemia are AEs that merit monitoring. To point out the most important topics for future research on GCs, a research agenda of 11 research questions has been formulated through 2 additional Delphi rounds (table 6).

## ACKNOWLEDGEMENTS

Professor H Capell, Centre for Rheumatic Diseases, Royal Infirmary Glasgow, Scotland, UK, participated in the taskforce during the Delphi exercises.

## Authors' affiliations

**J N Hoes, J W G Jacobs, J W J Bijlsma**, Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, The Netherlands  
**M Boers**, Department of Clinical Epidemiology and Biostatistics, VU University Medical Centre, Amsterdam, The Netherlands  
**D Boumpas**, Departments of Internal Medicine and Rheumatology, Clinical Immunology and Allergy, University of Crete, Greece  
**F Buttgeriet**, Department of Rheumatology and Clinical Immunology, Charité Universitätsmedizin Berlin, Germany  
**N Caeyers**, EULAR Social Leagues Patients' Representative, Belgium  
**E H Choy**, Sir Alfred Baring Garrod Clinical Trials Unit, Academic Department of Rheumatology, King's College London, UK  
**M Cutolo**, Research Laboratory and Division of Rheumatology, Department of Internal Medicine, University of Genoa, Italy  
**J A P Da Silva**, Reumatologia, Hospitais da Universidade de Coimbra, Portugal  
**G Esselens, R Westhovens**, Department of Rheumatology, University Hospitals KU Leuven, Belgium  
**L Guillemin**, Service de Médecine Interne, Centre de Référence National “Plan Maladies Rares”, Vascularites et Sclérodémie, Hôpital Cochin, Assistance Publique—Hôpitaux de Paris, Université Paris-V, France  
**I Hafstrom**, Department of Rheumatology, Karolinska Institute at Karolinska University Hospital Huddinge, Stockholm, Sweden  
**J R Kirwan**, University of Bristol Academic Rheumatology Unit, Bristol Royal Infirmary, Bristol, UK  
**J Rovinsky**, National Institute of Rheumatic Diseases Piest'any, Slovak Republic  
**A Russell**, Department of Medicine, Division of Rheumatology, University of Alberta, Edmonton, Alberta, Canada  
**K G Saag**, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, USA  
**B Svensson**, Department of Rheumatology, University of Lund, Lund, Sweden  
**H Zeidler**, Division of Rheumatology, Medizinische Hochschule Hannover, Hannover, Germany

Competing interests: None declared.

This is an abbreviated version of the article; the full version is available online at <http://ard.bmj.com/supplemental>

## REFERENCES

- 1 **Boompas DT**, Chrousos GP, Wilder RL, Cupps TR, Balow JE. Glucocorticoid therapy for immune-mediated diseases: basic and clinical correlates. *Ann Intern Med* 1993;**119**:1198–208.
- 2 **Kirwan JR**, Bijlsma JWJ, Boers M, Shea BJ. Effects of glucocorticoids on radiological progression in rheumatoid arthritis. *Cochrane Database Syst Rev* 2007.
- 3 **Pensabeni-Jasper T**, Panush RS. Review: corticosteroid usage: observations at a community hospital. *Am J Med Sci* 1996;**311**:234–9.
- 4 **Dougados M**, Betteridge N, Burmester GR, Euler-Ziegler L, Guillemin F, Hirvonen J, et al. EULAR standardised operating procedures for the elaboration, evaluation, dissemination, and implementation of recommendations endorsed by the EULAR standing committees. *Ann Rheum Dis* 2004;**63**:1172–6.
- 5 **Anon**. Good safety information practices. In: *Guidelines for preparing core clinical safety information on drugs—Report of CIOMS Working Group III*. Geneva: WHO, 1995.
- 6 **Curtis JR**, Andrew OW, Jeroan A, Johannes WB, Allison F, Varghese G, et al. Population-based assessment of adverse events associated with long-term glucocorticoid use. *Arthritis Care Res* 2006;**55**:420–6.
- 7 **Merlino LA**, Bagchi I, Taylor TN, Utrie P, Chrischilles E, Sumner W, et al. Preference for fractures and other glucocorticoid-associated adverse effects among rheumatoid arthritis patients. *Med Decis Making* 2001;**21**:122–32.
- 8 **Lindroth Y**, Brattstrom M, Bellman I, Ekstaf G, Olofsson Y, Strombeck B, et al. A problem-based education program for patients with rheumatoid arthritis: evaluation after three and twelve months. *Arthritis Care Res* 1997;**10**:325–32.
- 9 **Burma MR**, Rachow JW, Kolluri S, Saag KG. Methotrexate patient education: a quality improvement study. *Arthritis Care Res* 1996;**9**:216–22.
- 10 **McPherson CJ**, Higginson IJ, Hearn J. Effective methods of giving information in cancer: A systematic literature review of randomized controlled trials. *J Public Health Med* 2001;**23**:227–34.
- 11 **O'Neil CK**, Poirer TI. Impact of patient knowledge, patient-pharmacist relationship, and drug perceptions on adverse drug therapy outcomes. *Pharmacotherapy* 1998;**18**:333–40.
- 12 **Silvestri A**, Galetta P, Cerquetani E, Marazzi G, Patrizi R, Fini M, et al. Report of erectile dysfunction after therapy with beta-blockers is related to patient knowledge of side effects and is reversed by placebo. *Eur Heart J* 2003;**24**:1928–32.
- 13 **Myklebust G**, Gran JT. Prednisolone maintenance dose in relation to starting dose in the treatment of polymyalgia rheumatica and temporal arteritis. A prospective two-year study in 273 patients. *Scand J Rheumatol* 2001;**30**:260–7.
- 14 **Kyle V**, Hazleman BL. Treatment of polymyalgia rheumatica and giant cell arteritis. I. Steroid regimens in the first two months. *Ann Rheum Dis* 1989;**48**:658–61.
- 15 **Kremers HM**, Reinalda MS, Crowson CS, Zinsmeister AR, Hunder GG, Gabriel SE. Relapse in a population based cohort of patients with polymyalgia rheumatica. *J Rheumatol* 2005;**32**:65–73.
- 16 **Nesher G**, Rubinow A, Sonnenblick M. Efficacy and adverse effects of different corticosteroid dose regimens in temporal arteritis: a retrospective study. *Clin Exp Rheumatol* 1997;**15**:303–6.
- 17 **Hagen M**, Hjelmestaeth J, Jenssen T, Markrid L, Hartmann A. A 6-year prospective study on new onset diabetes mellitus, insulin release and insulin sensitivity in renal transplant recipients. *Nephrol Dial Transplant* 2003;**18**:2154–9.
- 18 **Hjelmestaeth J**, Hagen M, Hartmann A, Midtvedt K, Egeland T, Jenssen T. The impact of impaired insulin release and insulin resistance on glucose intolerance after renal transplantation. *Clin Transplant* 2002;**16**:389–96.
- 19 **Midtvedt K**, Hjelmestaeth J, Hartmann A, Lund K, Paulsen D, Egeland T, et al. Insulin resistance after renal transplantation: the effect of steroid dose reduction and withdrawal. *J Am Soc Nephrol* 2004;**15**:3233–9.
- 20 **Taler SJ**, Textor SC, Canzanello VJ, Schwartz L, Porayko M, Wiesner RH, et al. Role of steroid dose in hypertension early after liver transplantation with tacrolimus (FK506) and cyclosporine. *Transplantation* 1996;**62**:1588–92.
- 21 **Kowanko IC**, Knapp MS, Pownall R, Swannell AJ. Domiciliary self-measurement in the rheumatoid arthritis and the demonstration of circadian rhythmicity. *Ann Rheum Dis* 1982;**41**:453–5.
- 22 **Straub RH**, Cutolo M. Circadian rhythms in rheumatoid arthritis: Implications for pathophysiology and therapeutic management. *Arthritis Rheum* 2007;**56**:399–408.
- 23 **Arvidson NG**, Gudbjörnsson B, Larsson A, Hällgren R. The timing of glucocorticoid administration in rheumatoid arthritis. *Ann Rheum Dis* 1997;**56**:27–31.
- 24 **Buttgereit F**, Doering G, Schaeffer A, Szechinski J, Alten R. New modified-release (MR) tablet formulation of prednisone significantly reduces duration of morning stiffness compared to standard prednisone in subjects with rheumatoid arthritis (RA). *Arthritis Rheum* 2006;**54**:4036 (abstract).
- 25 **Da Silva JA**, Jacobs JW, Kirwan JR, Boers M, Saag KG, Ines LB, et al. Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data. *Ann Rheum Dis* 2006;**65**:285–93.
- 26 **Homik J**, Suarez-Almazor ME, Shea B, Cranney A, Wells G, Tugwell P. Calcium and vitamin D for corticosteroid-induced osteoporosis. *Cochrane Database Syst Rev* 2000;CD000952.
- 27 **de Nijs RN**, Jacobs JW, Algra A, Lems WF, Bijlsma JW. Prevention and treatment of glucocorticoid-induced osteoporosis with active vitamin D3 analogues: a review with meta-analysis of randomized controlled trials including organ transplantation studies. *Osteoporos Int* 2004;**15**:589–602.
- 28 **Homik J**, Cranney A, Shea B, Tugwell P, Wells G, Adachi R, et al. Bisphosphonates for steroid induced osteoporosis. *Cochrane Database Syst Rev* 2000;CD001347.
- 29 **Kvien TK**, Haugeberg G, Uhlig T, Falch JA, Halse JI, Lems WF, et al. Data driven attempt to create a clinical algorithm for identification of women with rheumatoid arthritis at high risk of osteoporosis. *Ann Rheum Dis* 2000;**59**:805–11.
- 30 **van Staa TP**, Laan RF, Barton IP, Cohen S, Reid DM, Cooper C. Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. *Arthritis Rheum* 2003;**48**:3224–9.
- 31 **Anon**. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis. *Arthritis Rheum* 2001;**44**:1496–503.
- 32 **Geusens PP**, de Nijs RN, Lems WF, Laan RF, Struijs A, van Staa TP, et al. Prevention of glucocorticoid osteoporosis: a consensus document of the Dutch Society for Rheumatology. *Ann Rheum Dis* 2004;**63**:324–5.
- 33 **Eastell R**, Reid DM, Compston J, Cooper C, Fogelman I, Francis RM, et al. A UK Consensus Group on management of glucocorticoid-induced osteoporosis: an update. *J Intern Med* 1998;**244**:271–92.
- 34 **Hooper L**, Brown TJ, Elliott R, Payne K, Roberts C, Symmons D. The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs: systematic review. *BMJ* 2004;**329**:948.
- 35 **Rostom A**, Dube C, Wells G, Tugwell P, Welch V, Jolicoeur E, et al. Prevention of NSAID-induced gastroduodenal ulcers. *Cochrane Database Syst Rev* 2002;CD002296.
- 36 **Bombardier C**, Laine L, Reicin A, Shapiro D, Burgos VR, Davis B, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. *N Engl J Med* 2000;**343**:1520–8.
- 37 **Silverstein FE**, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. *JAMA* 2000;**284**:1247–55.
- 38 **Deeks JJ**, Smith LA, Bradley MD. Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials. *BMJ* 2002;**325**:619.
- 39 **Spiegel BMR**, Farid M, Dulai GS, Gralnek IM, Kanwal F. Comparing rates of dyspepsia with coxibs vs NSAID+PPI: A meta-analysis. *Am J Med* 2006;**119**:448.
- 40 **Bresalier RS**, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. *N Engl J Med* 2005;**352**:1092–102.
- 41 **Cannon CP**, Curtis SP, FitzGerald GA, Krum H, Kaur A, Bolognese JA, et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. *Lancet* 2006;**368**:1771–81.
- 42 **Garner SE**, Fidan DD, Frankish RR, Judd MG, Towheed TE, Tugwell P, et al. Rofecoxib for rheumatoid arthritis. *Cochrane Database of Systematic Reviews: Reviews* 2005 Issue 1 John Wiley, Chichester, UK. DOI: 10.1002/14651858 CD003685 pub2 2005.
- 43 **Kearney PM**, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. *Br Med J* 2006;**332**:1302–5.
- 44 **McGettigan P**, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. *JAMA* 2006;**296**:1633–44.
- 45 **Solomon SD**, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. *N Engl J Med* 2005;**352**:1071–80.
- 46 **Slaney G**, Brooke BN. Postoperative collapse due to adrenal insufficiency following cortisone therapy. *Lancet* 1957;**272**:1167–70.
- 47 **Cutolo M**, Sulli A, Pizzorni C, Cravioito C, Straub RH. Hypothalamic-pituitary-adrenocortical and gonadal functions in rheumatoid arthritis. *Ann NY Acad Sci* 2003;**992**:107–17.
- 48 **Anon**. *AHFS drug information*. Bethesda: 2001.
- 49 **Mader R**, Lavi I, Luboshitzky R. Evaluation of the pituitary-adrenal axis function following single intraarticular injection of methylprednisolone. *Arthritis Rheum* 2005;**52**:924–8.
- 50 **Ackerman GL**, Nolsn CM. Adrenocortical responsiveness after alternate-day corticosteroid therapy. *N Engl J Med* 1968;**278**:405–9.
- 51 **Schlaghecke R**, Kornely E, Santen RT, Ridderskamp P. The effect of long-term glucocorticoid therapy on pituitary-adrenal responses to exogenous corticotropin-releasing hormone. *N Engl J Med* 1992;**326**:226–30.
- 52 **DeMarco PJ**, Weisman MH, Seibold JR, Furst DE, Wong WK, Hurwitz EL, et al. Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial. *Arthritis Rheum* 2002;**46**:2983–9.
- 53 **Niemann LK**. Up to Date (<http://www.uptodate.com>): Treatment of adrenal insufficiency. (accessed 19 Oct 2006).
- 54 **Karlsson C**, Obrant KJ, Karlsson M. Pregnancy and lactation confer reversible bone loss in humans. *Osteoporos Int* 2001;**12**:828–34.
- 55 **Tuffnell DJ**, West J, Walkinshaw SA. Treatments for gestational diabetes and impaired glucose tolerance in pregnancy. *Cochrane Database Syst Rev* 2003;CD003395.
- 56 **Sibai BM**. Diagnosis and management of gestational hypertension and preeclampsia. *Obstet Gynecol* 2003;**102**:181–92.
- 57 **Blanford AT**, Murphy BE. In vitro metabolism of prednisolone, dexamethasone, betamethasone, and cortisol by the human placenta. *Am J Obstet Gynecol* 1977;**127**:264–7.



- 58 **Pinsky L**, Digeorge AM. Cleft palate in the mouse: a teratogenic index of glucocorticoid potency. *Science* 1965;**147**:402–3.
- 59 **Pirson Y**, Van LM, Ghysen J, Squifflet JP, Alexandre GP, van Ypersele de SC. Retardation of fetal growth in patients receiving immunosuppressive therapy. *N Engl J Med* 1985;**313**:328.
- 60 **Anon**. Food and Drug Administration. FDA categories for drug use in pregnancy. 44, 37434–67. 2006. *Fed Regist* 1980.
- 61 **Schatz M**, Patterson R, Zeitz S, O'Rourke J, Melam H. Corticosteroid therapy for the pregnant asthmatic patient. *JAMA* 1975;**233**:804–7.
- 62 **Schmidt PL**, Sims ME, Strassner HT, Paul RH, Mueller E, McCart D. Effect of antepartum glucocorticoid administration upon neonatal respiratory distress syndrome and perinatal infection. *Am J Obstet Gynecol* 1984;**148**:178–86.
- 63 **Katz FH**, Duncan BR. Letter: Entry of prednisone into human milk. *N Engl J Med* 1975;**293**:1154.
- 64 **Ost L**, Wettrell G, Bjorkhem I, Rane A. Prednisolone excretion in human milk. *J Pediatr* 1985;**106**:1008–11.
- 65 **Anon**. Transfer of drugs and other chemicals into human milk. *Pediatrics* 2001;**108**:776–89.
- 66 **Simon D**, Fernando C, Czernichow P, Prieur AM. Linear growth and final height in patients with systemic juvenile idiopathic arthritis treated with longterm glucocorticoids. *J Rheumatol* 2002;**29**:1296–300.
- 67 **Alemzadeh N**, Rekers-Mombarg LT, Mearin ML, Wit JM, Lamers CB, van Hozegand RA. Adult height in patients with early onset of Crohn's disease. *Gut* 2002;**51**:26–9.
- 68 **Allen DB**, Mullen M, Mullen B. A meta-analysis of the effect of oral and inhaled corticosteroids on growth. *J Allergy Clin Immunol* 1994;**93**:967–76.
- 69 **Lai HC**, FitzSimmons SC, Allen DB, Kosorok MR, Rosenstein BJ, Campbell PW, *et al*. Risk of persistent growth impairment after alternate-day prednisone treatment in children with cystic fibrosis. *N Engl J Med* 2000;**342**:851–9.
- 70 **Al-Mutair A**, Bahabri S, Al-Mayouf S, Al-Ashwal A. Efficacy of recombinant human growth hormone in children with juvenile rheumatoid arthritis and growth failure. *J Pediatr Endocrinol Metab* 2000;**13**:899–905.
- 71 **Bechtold S**, Ripperger P, Muhlbayer D, Truckenbrodt H, Hafner R, Butenandt O, *et al*. GH therapy in juvenile chronic arthritis: results of a two-year controlled study on growth and bone. *J Clin Endocrinol Metab* 2001;**86**:5737–44.
- 72 **Bechtold S**, Ripperger P, Hafner R, Said E, Schwarz HP. Growth hormone improves height in patients with juvenile idiopathic arthritis: 4-year data of a controlled study. *J Pediatr* 2003;**143**:512–9.
- 73 **Grote FK**, Van Suijlekom-Smit LW, Mul D, Hop WC, Ten CR, Oostdijk W, *et al*. Growth hormone treatment in children with rheumatic disease, corticosteroid induced growth retardation, and osteopenia. *Arch Dis Child* 2006;**91**:56–60.
- 74 **Simon D**, Fernando C, Czernichow P, Prieur AM. Linear growth and final height in patients with systemic juvenile idiopathic arthritis treated with longterm glucocorticoids. *J Rheumatol* 2002;**29**:1296–300.
- 75 **Simon D**, Lucidarme N, Prieur AM, Ruiz JC, Czernichow P. Effects on growth and body composition of growth hormone treatment in children with juvenile idiopathic arthritis requiring steroid therapy. *J Rheumatol* 2003;**30**:2492–9.
- 76 **Allen DB**, Goldberg BD. Stimulation of collagen synthesis and linear growth by growth hormone in glucocorticoid-treated children. *Pediatrics* 1992;**89**:416–21.
- 77 **Allen DB**, Julius JR, Breen TJ, Attie KM. Treatment of glucocorticoid-induced growth suppression with growth hormone. National Cooperative Growth Study. *J Clin Endocrinol Metab* 1998;**83**:2824–9.
- 78 **Allen DB**. Growth hormone therapy for short stature: is the benefit worth the burden? *Pediatrics* 2006;**118**:343–8.
- 79 **Zhang W**, Doherty M, Arden N, Bannwarth B, Bijlsma J, Gunther KP, *et al*. EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCSIT). *Ann Rheum Dis* 2005;**64**:669–81.
- 80 **Zhang W**, Doherty M, Bardin T, Pascual E, Barskova V, Conaghan P, *et al*. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCSIT). *Ann Rheum Dis* 2006;**65**:1312–24.
- 81 **Zhang W**, Doherty M, Leeb BF, Alekseeva L, Arden NK, Bijlsma JW, *et al*. EULAR evidence based recommendations for the management of hand osteoarthritis — report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCSIT). *Ann Rheum Dis* 2007;**66**:377–88.
- 82 **Zhang W**, Doherty M, Pascual E, Bardin T, Barskova V, Conaghan P, *et al*. EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCSIT). *Ann Rheum Dis* 2006;**65**:1301–11.
- 83 **Shekelle PG**, Woolf SH, Eccles M, Grimshaw J. Clinical guidelines: developing guidelines. *BMJ* 1999;**318**:593–6.
- 84 **Saag KG**, Koehnke R, Caldwell JR, Brasington R, Burmeister LF, Zimmerman B, *et al*. Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. *Am J Med* 1994;**96**:115–23.

### BNF for Children 2006, second annual edition

In a single resource:

- guidance on drug management of common childhood conditions
- hands-on information on prescribing, monitoring and administering medicines to children
- comprehensive guidance covering neonates to adolescents

For more information please go to **bnf.org**